ISTANBUL — A novel ocular biometer that combines a Purkinje imaging method and an OCT device has the potential to produce highly accurate and reproducible measurements for IOL power calculation, according to one speaker.“It might be a promising solution for both normal and challenging cases, such as post-LASIK eyes or implantation of toric IOLs,” Michael Mrochen, PhD, said at the winter meeting of the European Society of Cataract and Refractive Surgeons.
IRIDEX Corporation today announced that it will debut Cyclo G6, the Company’s first laser platform dedicated to the treatment of glaucoma, at this year’s annual congress of the American Glaucoma Society.
ISTANBUL – At the ESCRS Winter Meeting, Farhad Hafezi, MD, PhD, gives pearls on how to make the most of crosslinking, as a standalone procedure or in combination with vision enhancing procedures. There is no standardized reaction of corneas to crosslinking, and case by case surgeons should be able to evaluate whether vision enhancing procedures should be performed or not, and if they are better performed simultaneously or consequentially to crosslinking.
Bayer HealthCare is pleased that NICE has recognised the benefits of EYLEA (aflibercept solution for injection) for the treatment of visual impairment due to diabetic macular oedema (DMO) according…
An ophthalmology research team at the University of Wisconsin-Madison took part in a nationwide clinical trial comparing treatments for a form of diabetic eye disease. The study found that three commonly used drugs perform much the same for those with …
In the first clinical trial directly comparing three drugs most commonly used to treat diabetic macular edema, researchers found all were effective in improving vision and preventing vision loss.